Skip to main content
Erschienen in: Journal of Neuro-Oncology 3/2020

13.04.2020 | Clinical Study

The effect of mTOR inhibition on obstructive hydrocephalus in patients with tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA)

verfasst von: Danielle R. Weidman, Sunitha Palasamudram, Maria Zak, Robyn Whitney, Blathnaid McCoy, Eric Bouffet, Michael Taylor, Manohar Shroff, Ute Bartels

Erschienen in: Journal of Neuro-Oncology | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Mammalian target of rapamycin inhibitors (mTORi) are known to effectively reduce the size of subependymal giant cell astrocytomas (SEGAs), which are benign brain lesions associated with Tuberous Sclerosis Complex (TSC) that commonly cause obstructive hydrocephalus (OH). This retrospective case series reviews an institutional experience of the effect of mTORi on OH in patients with TSC-related SEGA.

Methods

Thirteen of 16 identified patients with TSC-related SEGA treated with mTORi from October 2007 to December 2018 were included. Serial magnetic resonance imaging (MRI) and clinical charts were reviewed to correlate symptoms and signs of increased intracranial pressure (iICP) with ventriculomegaly on MRI. A proposed ventriculomegaly scale was used: none (< 7 mm), mild (7–10 mm), moderate (11–30 mm), and severe (> 30 mm). OH was defined as moderate or severe ventriculomegaly, based on the largest measurement.

Results

Patients’ median age at start of mTORi was 13 (6–17) years and five (38%) patients were female. Eight patients had OH at the time of mTORi initiation, five of whom were asymptomatic. Six patients had improvement of hydrocephalus on serial MRI imaging with mTORi therapy, while seven patients had no change based on the ventriculomegaly scale used. All three patients who presented with symptoms of iICP and had OH also had papilledema. None had worsening of hydrocephalus or required shunt placement. Out of five patients with symptoms of iICP, four avoided surgery.

Conclusion

Most patients had asymptomatic OH at the time of diagnosis, and ventricular enlargement was not correlated with iICP symptoms. mTORi was successful for treatment of OH from TSC-related SEGA, even in the setting of acute symptoms of iICP.
Literatur
1.
Zurück zum Zitat Hyman MH, Whittemore VH (2000) National institutes of health consensus conference: tuberous sclerosis complex. Arch Neurol 57:662–665CrossRef Hyman MH, Whittemore VH (2000) National institutes of health consensus conference: tuberous sclerosis complex. Arch Neurol 57:662–665CrossRef
4.
Zurück zum Zitat Krueger DA, Mcare MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T (2010) Franz DN (2010) Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 363:1801–1811CrossRef Krueger DA, Mcare MM, Holland K, Agricola K, Tudor C, Mangeshkar P, Wilson KA, Byars A, Sahmoud T (2010) Franz DN (2010) Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 363:1801–1811CrossRef
11.
Zurück zum Zitat Kasper E, Laviv Y, Sebai M-AE, Lin N, Butler W (2017) Subependymal giant cell astrocytoma: associated hyperproteinorrhachia causing shunt failures and nonobstructive hydrocephalus—report of successful treatment with long-term follow-up. Asian J Neurosurg 12(4):746–750CrossRef Kasper E, Laviv Y, Sebai M-AE, Lin N, Butler W (2017) Subependymal giant cell astrocytoma: associated hyperproteinorrhachia causing shunt failures and nonobstructive hydrocephalus—report of successful treatment with long-term follow-up. Asian J Neurosurg 12(4):746–750CrossRef
13.
Zurück zum Zitat Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Whittemore VH, Thiele EA, Ford JP, Shah G, Cauwel H, Lebwohl D, Sahmoud T, Jozwiak S (2013) Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 381(9861):125–132. https://doi.org/10.1016/s0140-6736(12)61134-9 CrossRefPubMed Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, Kuperman R, Witt O, Kohrman MH, Flamini JR, Wu JY, Curatolo P, de Vries PJ, Whittemore VH, Thiele EA, Ford JP, Shah G, Cauwel H, Lebwohl D, Sahmoud T, Jozwiak S (2013) Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 381(9861):125–132. https://​doi.​org/​10.​1016/​s0140-6736(12)61134-9 CrossRefPubMed
17.
Zurück zum Zitat Sari E, Sari S, Akgun V, Ozcan E, Ince S, Babacan O, Saldir M, Acikel C, Basbozkurt G, Yesilkaya S, Kilic C, Kara K, Vurucu S, Kocaoglu M, Yesilkaya E (2015) Measures of ventricles and evans' index: from neonate to adolescent. Pediatr Neurosurg 50(1):12–17. https://doi.org/10.1159/000370033 CrossRefPubMed Sari E, Sari S, Akgun V, Ozcan E, Ince S, Babacan O, Saldir M, Acikel C, Basbozkurt G, Yesilkaya S, Kilic C, Kara K, Vurucu S, Kocaoglu M, Yesilkaya E (2015) Measures of ventricles and evans' index: from neonate to adolescent. Pediatr Neurosurg 50(1):12–17. https://​doi.​org/​10.​1159/​000370033 CrossRefPubMed
19.
Zurück zum Zitat Di Rocco C, Caldarelli M, Ceddia A (1989) "Occult" hydrocephalus in children. Childs Nerv Syst 5:71–75CrossRef Di Rocco C, Caldarelli M, Ceddia A (1989) "Occult" hydrocephalus in children. Childs Nerv Syst 5:71–75CrossRef
20.
Zurück zum Zitat Kirkpatrick M, Engleman H, Minns RA (1989) Symptoms and signs of progressive hydrocephalus. Arch Dis Child 64:124–128CrossRef Kirkpatrick M, Engleman H, Minns RA (1989) Symptoms and signs of progressive hydrocephalus. Arch Dis Child 64:124–128CrossRef
22.
Zurück zum Zitat Goh S, Butler W, Thiele EA (2004) Subependymal giant cell tumors in tuberous sclerosis complex. Neurology 63:1457–1461CrossRef Goh S, Butler W, Thiele EA (2004) Subependymal giant cell tumors in tuberous sclerosis complex. Neurology 63:1457–1461CrossRef
25.
Zurück zum Zitat Di Rocco C, Iannelli A, Marchese E (1995) On the treatment of subependymal giant cell astrocytomas and associated hydrocephalus in tuberous sclerosis. Pediatr Neurosurg 23:115–121CrossRef Di Rocco C, Iannelli A, Marchese E (1995) On the treatment of subependymal giant cell astrocytomas and associated hydrocephalus in tuberous sclerosis. Pediatr Neurosurg 23:115–121CrossRef
26.
Zurück zum Zitat French JA, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R, Curatolo P, de Vries PJ, Dlugos DJ, Berkowitz N, Voi M, Peyrard S, Pelov D, Franz DN (2016) Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet 388(10056):2153–2163. https://doi.org/10.1016/s0140-6736(16)31419-2 CrossRefPubMed French JA, Lawson JA, Yapici Z, Ikeda H, Polster T, Nabbout R, Curatolo P, de Vries PJ, Dlugos DJ, Berkowitz N, Voi M, Peyrard S, Pelov D, Franz DN (2016) Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet 388(10056):2153–2163. https://​doi.​org/​10.​1016/​s0140-6736(16)31419-2 CrossRefPubMed
Metadaten
Titel
The effect of mTOR inhibition on obstructive hydrocephalus in patients with tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA)
verfasst von
Danielle R. Weidman
Sunitha Palasamudram
Maria Zak
Robyn Whitney
Blathnaid McCoy
Eric Bouffet
Michael Taylor
Manohar Shroff
Ute Bartels
Publikationsdatum
13.04.2020
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 3/2020
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-020-03487-8

Weitere Artikel der Ausgabe 3/2020

Journal of Neuro-Oncology 3/2020 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.